Fresh off a $3 million fundraise, Stratatech Corp. plans to begin Phase 2b clinical trials of its genetically engineered human-skin substitute. The Madison, Wis.-based company said it plans to begin the trials of its StrataGraft skin substitute, which is designed for patients suffering from burns or other sever wounds, in the second half of this […]
Stratatech Corp. has raised $3 million to continue developing a genetically engineered human skin substitute, according to a regulatory filing. The fundraise comes in the form of debt, options, warrants or other securities, the document filed with the Securities and Exchange Commission said. Robert Barnard, a company official, declined comment on the funding. The company’s […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.